FierceBiotech 2026年4月15日 FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
FierceBiotech 2026年4月14日 Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
FierceBiotech 2026年4月14日 Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
FierceBiotech 2026年4月14日 Harbinger Health raises $100M for new suite of blood-based cancer detection tests
FierceBiotech 2026年4月14日 Boehringer, Amgen discard early immunology candidates over lack of clinical potential
FierceBiotech 2026年4月13日 Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets
FierceBiotech 2026年4月13日 Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
FierceBiotech 2026年4月13日 AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
FierceBiotech 2026年4月13日 Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
FierceBiotech 2026年4月13日 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech 2026年4月13日 Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
FierceBiotech 2026年4月13日 Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates